Skip to main content


We're creating a new version of this page. See preview

  • Oral presentation
  • Open Access

Protein structure-based drug design: applications, limitations and future developments

Chemistry Central Journal20082 (Suppl 1) :S15

  • Published:


  • Virtual Screening
  • Plasma Protein Binding
  • Structural Knowledge
  • P450 Inhibition
  • Additional Aspect

Protein structure-based drug design has been contributing to the drug discovery process since the early 1990s. Structural knowledge on the exact interactions of drugs with their target proteins has been applied mainly to predict potency changes of chemically modified lead compounds.

With the 3D-structural information available today, additional aspects of the drug discovery process become predictable. Target-based virtual screening is being applied to identify new unexpected lead structures. Selectivity of compounds between homologous or orthologous proteins can be predicted, offering new possibilities to design selective compounds or predict the suitability of animal models for pharmacodynamic studies. Also the number of x-ray structures of proteins relevant for ADMET properties of drug molecules has remarkably increased during the last few years. This development offers the possibility to modulate or rationally design out unwanted ADMET properties. This covers aspects such as plasma protein binding, cytochrome P450 inhibition, metabolism and induction.

In this review style talk, a number of recent examples will be presented that demonstrate the utility of protein structure information during the drug discovery process, from lead identification to lead optimization and from pharmacodynamics to pharmacokinetic studies.

Authors’ Affiliations

Bayer HealthCare AG, Director, Medicinal Chemistry, 40296 Wuppertal, Germany


© Hillisch 2008